PT - JOURNAL ARTICLE AU - Bishop, Charles W. AU - Ashfaq, Akhtar AU - Melnick, Joel Z. AU - Vazquez-Escarpanter, Enrique AU - Fialkow, Jonathan A. AU - Strugnell, Stephen A. AU - Choe, John AU - Kalantar-Zadeh, Kamyar AU - Federman, Noah C. AU - Ng, David AU - Adams, John S. TI - Results From the REsCue Trial: A Randomized Controlled Trial with Extended-Release Calcifediol in Symptomatic Outpatients with COVID-19 AID - 10.1101/2022.01.31.22270036 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.31.22270036 4099 - http://medrxiv.org/content/early/2022/02/05/2022.01.31.22270036.short 4100 - http://medrxiv.org/content/early/2022/02/05/2022.01.31.22270036.full AB - Importance The benefit of vitamin D treatment for coronavirus disease 2019 (COVID-19) remains unclear.Objective To investigate the effect of raising serum total 25-hydroxyvitamin D (25D) to 50-100 ng/mL with oral extended-release calcifediol (ERC) on time to symptom resolution in mild to moderate COVID-19.Design, Setting, and Participants A multicenter, randomized, double-blind, placebo-controlled study evaluated treatment of 160 outpatients with COVID-19 diagnosed between November 2020 and October 2021.Interventions Patients were treated for 4 weeks with ERC (30 mcg/capsule; 300 mcg on Days 1-3 and 60 mcg on Days 4-27) or placebo.Outcome Measures Primary endpoints were raising serum 25D to ≥50 ng/mL at Day 14 and resolution time for five aggregated symptoms. Secondary endpoints included resolution time for aggregated and individual symptoms as a function of serum 25D and changes in clinical biomarkers.Results 171 subjects randomized, 160 treated and 134 (65 ERC and 69 placebo) retained. Average age was 43 (range: 18-71); 59% female, 92% White, 80% Hispanic, 7% African-American, 1% Other, 76% overweight, 40% obese, 26% comorbidities, mean baseline 25D of 37±1 (SE) ng/mL. ERC increased mean 25D to 82±4 ng/mL (p<0.001) by Day 7; 88% of subjects attained a level ≥50 ng/mL; the placebo group trended lower. Resolution time for five aggregated symptoms was unchanged by ERC given that two composite non-respiratory symptoms responded poorly. Prespecified analyses showed that respiratory symptoms tended to resolve earlier when serum 25D levels reached ≤50 ng/mL, but statistical significance was limited by small sample size and non-compliance: 25D increased in seven placebo subjects (unauthorized supplementation) and none occurred in five ERC subjects (failure to dose). A post-hoc composite of three respiratory symptoms (trouble breathing, chest congestion and dry or hacking cough) resolved 3.0 days faster when 25D was elevated at Days 7 and 14 (p<0.05); chest congestion resolved 4.0 days faster with 25D increases of ≥25 ng/mL (p<0.05). Safety concerns including hypercalcemia were absent with ERC treatment.Conclusions and Relevance ERC was effective in increasing serum 25D in outpatients with COVID-19, which may have accelerated resolution of respiratory symptoms suggesting mitigation of COVID-19 pneumonia risk, findings which warrant further study.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: funding support was received from OPKO Health, Inc. (OPKO); Drs. Bishop, Ashfaq, Strugnell and Choe are employed by OPKO and have received stock options; Drs. Melnick and Kalantar-Zadeh are OPKO consultants; Dr. Ng is an employee of WuXi Clinical Trials engaged as a contractor for OPKO; Drs. Vazquez and Fialkow are paid OPKO clinical investigators; no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialNCT04551911Funding StatementThis study was funded by OPKO Health Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advarra (Columbia, MD), a central Institutional Review Board, gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll top-line data produced in the present study are contained in the manuscript. Additional analyses are ongoing as further laboratory data become available.